Setting up a unsecured bond facility of up to 5 billion yen with EVO FUND as the, issuer; issuing the Second Unsecured Ordinary Bond. Warrants for the 70th and 71st will be allocated to EVO FUND, with a revised exercise price linked to stock price. Funds will be mainly used for the development costs of Brincidovir and future clinical trial expenses. Designing a roughly 3-year funding plan with an eye toward new drug approval applications in 2028. Currently, additional measures may be taken depending on funding progress and stock price movement.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SinBio Pharmaceuticals, Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4582-20260817-01.pdf","jir_short_summary":"Setting up a unsecured bond facility of up to 5 billion yen with EVO FUND as the, issuer; issuing the Second Unsecured Ordinary Bond. Warrants for the 70th and 71st will be allocated to EVO FUND, with a revised exercise price linked to stock price. Funds will be mainly used for the development costs of Brincidovir and future clinical trial expenses. Designing a roughly 3-year funding plan with an eye toward new drug approval applications in 2028. Currently, additional measures may be taken depending on funding progress and stock price movement.","jir_summary":"### Overview of fundraising\nSinBio Pharmaceuticals adopts a fundraising scheme combining new warrant-attached bonds with an allocation to EVO FUND. The facility agreement allows unsecured bonds up to 5 billion yen, with the issuance of the Second Unsecured Ordinary Bond planned. The 70th and 71st warrants are allocated to EVO FUND, with an adjusted exercise price linked to the stock price. The funds will be primarily allocated to development costs for Brincidovir and future clinical trial expenses.\n\n### Outlook and risks\nFunding is part of a routine to support a roughly three-year development plan and to secure ongoing clinical trials toward a 2028 new drug approval. On the other hand, the actual amount of financing may vary depending on stock price movements, raising risks of share dilution and market impact. The third-party allotment is expected to cause dilution of over 25%, with input from a third-party committee.","jir_financial_highlights":"Total amount to be raised: 6,768,880,000\u5186 (Not available)\nTotal paid-in amount of the warrants: 2,880,000\u5186 (Not available)\nTotal use of raised funds: 6,768 (Not available)\nTotal number of warrants: 960,000 shares (Not available)\n\u6f5c\u5728\u682a\u5f0f\u6570\uff08\u767a\u884c\u6e08\u682a\u5f0f\u7dcf\u6570\uff09: 96,000,000\u682a (Not available)","jir_category":"","jir_hashtags":"#SinBioPharmaceuticals, #Fundraising, #Warrants, #Bonds, #BCVDevelopment","jir_key_figures":"6,768,880,000\u5186: \u8abf\u9054\u8cc7\u91d1\u984d\uff08\u7dcf\u984d\uff09\n96,000,000\u682a: \u7b2c70\u56de\u65b0\u682a\u4e88\u7d04\u6a29\u30fb\u7b2c71\u56de\u65b0\u682a\u4e88\u7d04\u6a29\u306e\u5168\u4ed8\u4e0e\u5f8c\u306e\u6f5c\u5728\u682a\u5f0f\u6570\n4\u5186\/2\u5186: \u7b2c70\u56de\u65b0\u682a\u4e88\u7d04\u6a29\u30fb\u7b2c71\u56de\u65b0\u682a\u4e88\u7d04\u6a29\u306e\u6255\u8fbc\u4fa1\u984d\n3\u5e74\u9593: \u8cc7\u91d1\u8abf\u9054\u671f\u9593\nEU\u30fbUS\u30fbUK\u3092\u542b\u3080\u81e8\u5e8a\u958b\u767a\u8a08\u753b\u306e\u5bfe\u8c61","jir_meta_title":"\u3010SinBio Pharmaceuticals\u3011Announcement of Fundraising Scheme\uff5cAugust 17, 2026","jir_meta_description":"SinBio Pharmaceuticals announces fundraising including issuance of warrants-attached bonds to EVO FUND. Purpose is to secure clinical development funds for Brincidovir, with a roughly three-year funding plan toward a 2028 regulatory submission.","jir_og_title":"\u3010SinBio Pharmaceuticals\u3011Funding Scheme Announcement\uff5cAugust 17, 2026","jir_og_description":"Announcement of fundraising combining warrants-attached bonds and third-party allotment. Main objective is securing clinical development funds for Brincidovir, detailing the funding plan toward regulatory submission.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-104833","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n